Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension

Journal of Hypertension

Volumn 15, Issue 1, 1997, Pages 93-97

  Küppers, Hartmut E ^a   Jäger, Bodo A ^a   Luszick, Joachim H ^a   Gräve, Michael A ^a   Hughes, Peter R ^a   Kaan, Elbert C ^a  

^a Solvay Pharmaceuticals GmbH   (Germany)

Author keywords

Ambulatory blood pressure measurement; Double blind clinical trial; Enalapril; Essential hypertension; Imidazoline I1 receptors; Moxonidine; Trough:peak ratio

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; MOXONIDINE;

ADULT; AGED; AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BORDERLINE HYPERTENSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; XEROSTOMIA;

EID: 0031038675     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199715010-00010     Document Type: Article

References (14)

1. 1-imidazoline sites. J Pharmacol Exp Ther 1992, 264:172-182.
2. 1-imidazoline agonist Cardiovasc Drugs Ther 1994, 8 (suppl 1):27-42.
3. Mitrovic V, Patyna W, Hüting J, Schlepper W: Haemodynamic and neurohormonal effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther 1991, 5:967-972.
4. Zanchetti A on behalf of the Italian Nifedipine GITS Study Group: Trough:peak ratio of the blood pressure response to dihydropyridine calcium antagonists. J Hypertens 1994, 12 (suppl 8):S97-S106.
5. Omboni S, Parati G, Zanchetti A, Mancia G: Calculation of trough:peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects. J Hypertens 1995, 13:1105-1112.
6. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Morning peak in the incidence of myocardial infarction: experience in the ISIS-2 trial. Eur Heart J 1992, 13:594-598.
7. Willich SN, Levy D, Rocco MB, Tofler GH, Stone PH, Muller JE: Circadian variance in the incidence of sudden death in the Framingham Heart Study population. Am J Cardiol 1987, 60:801-806.
8. Behar S, Halabi M, Reicher-Reiss H, Zion M, Kaplinsky E, Mandelzweig L et al.: Circadian variation and possible triggers of onset of myocardial infarction: SPRINT Study Group. Am J Med 1993, 94:395-400.
9. Division of Cardio-Renal Products, Food and Drug Administration: Proposed Guidelines for the Clinical Evaluation of Antihypertensive Drugs. Rockville, MD: USA Department of Health and Human Services; 1988.
10. Zannad F: Trandolapril: how does it differ from other angiotensin converting enzyme inhibitors? Drugs 1993, 46 (suppl 2):172-182.
11. Frei M, Küster L, Gardosch von Krosigk P-P, Koch HF, Küppers H: Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect J Cardiovasc Pharmacol 1994, 24 (suppl 1):S25-S28.
12. Prichard BNC, Simmons R, Rooks M, Haworth DA, Laws D, Wonnacott S: A double-blind comparison of moxonidine and atenolol in the management of patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1992, 20 (suppl 4):S45-S49.
13. Kraft K, Vetter H: Twenty-four-hour blood pressure profiles in patients with mild-to-moderate hypertension: moxonidine versus captopril. J Cardiovasc Pharmacol 1994, 24 (suppl 1):S29-S33.
14. Wolf R: The treatment of hypertensive patients with a calcium antagonist or moxonidine: a comparison. J Cardiovasc Pharmacol 1992, 20 (suppl 4):S45-S49.